Thrombotic recurrences and bleeding events in APS vascular patients: A review from the literature and a comparison with the APS piedmont cohort

Autoimmunity Reviews

Volumn 12, Issue 8, 2013, Pages 826-831

  Bazzan, M ^a   Vaccarino, A ^a   Stella, S ^a   Bertero, M T ^b   Carignola, R ^c   Montaruli, B ^b   Roccatello, D ^d   Shoenfeld, Y ^e   Osvaldo, Giachino ^f   Fabio, Marletto ^f   Simone, Baldovino ^f   Luisa, Sosso ^f   Luca, Marozio ^f   Valeria, Data ^f   Giuseppe, Guida ^f   Patrizia, Bigo ^f   Cristiana, Rollino ^f   Michela, Ferro ^f   Loredana, Colla ^f   Eirini, Karvela ^f   Raffaele, Pellerito ^f   Emanuela, Bellis ^f   Aldo, Maina ^f   Valentina, Donvito ^f   Barbara, Nicolino ^f   Piercarla, Schinco ^f   Piera, Sivera ^f   Anna, Kuzenko ^f   Emanuela, Napolitano ^f   Domenico, Cosseddu ^f   Cristiana, Marchese ^f   Nicoletta, Romeo ^f   Giulia, Seminara ^f   Maria, Stefanidou Erato ^f   Filippo, Molinari ^f   Laura, Contino ^f   Roberto, Santi ^f   Gabriella, Nallino Maria ^f   Roberta, Calvi ^f   Piero, Stratta ^f   Agata, Bizzocchi ^f   Flavio, Bobbio ^f   Sainaghi, Pier Paolo ^f   Daniele, Sola ^f   more..

^a S GIOVANNI BOSCO HOSPITAL   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c SAN LUIGI GONZAGA HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e SHEBA MEDICAL CENTER   (Israel)

^f NONE

Author keywords

Antiphospholipid syndrome; Thrombosis; Thrombotic recurrences

Indexed keywords

WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLEEDING; CARDIOVASCULAR RISK; FOLLOW UP; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; QUALITY CONTROL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

EID: 85027473271     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.11.007     Document Type: Review

References (43)

1. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972;1:75-95.
2. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an International Workshop. Arthritis Rheum 1999;42:1309-11.
3. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
4. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta M. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
5. Cervera R, Conti F, Doria A, Iaccarino L, Valesini G. Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev 2012;11:581-4.
6. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002;46:1019-27.
7. Cavestro C, Mica G, Molinari F, Bazzan M, Di Pietrantonj C, Aloi R, et al. Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost 2011;9:1350-4.
8. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
9. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237-42.
10. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011;118:4714-8.
11. Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011;10:664-8.
12. Bertero MT, Bazzan M, Carignola R, Montaruli B, Silvestro E, Sciascia S, et al. Antiphospholipid syndrome in North-west Italy (APS "Piedmont Cohort"): demographic features, risk factors, clinical and laboratory profile. Lupus 2012;21(7):804-7.
13. Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thromb Res 2005;115:3-8.
14. Erkan D, Lockshin MD. How much warfarin is enough in APS related thrombosis? Thromb Res 2004;114:435-42.
15. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome. A systematic review. JAMA 2006;295:1050-7.
16. Puente D, Pombo G, Forastiero R. Current management of antiphospholipid syndrome-related thrombosis. Expert Rev Cardiovasc Ther 2009;7:1551-8.
17. Tripodi A, De Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanism of action and treatment. J Intern Med 2011;270:110-22.
18. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GRV. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome. Arch Intern Med 2002;162:1164-9.
19. Turiel M, Sarzi-Puttini P, Peretti R, Rossi E, Atzeni F, Parsons W, et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke 2005;36:1490-4.
20. Forastiero R, Martinuzzo M, Pombo G, Puente D, Rossi A, Celebrin L, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin and risk of thrombosis. J Thromb Haemost 2005;3:1231-8.
21. Wittkowsky AK, Downing J, Blackburn J, Nutescu E. Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006;96:137-41.
22. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007;16:39-45.
23. Cervera R, Khamashta MA, Shoenfed Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009;68:1428-32.
24. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-8.
25. Giron-Gonzales JA, Garcia del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody:prospective analysis of 404 individuals. J Rheumatol 2004;31:1560-7.
26. Levine SR, Brey RL, Tilley SC, Thompson JL, Sacco RL, Sciacca RR, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576-84.
27. Cabral AR, Ruiz-Irastorza G, Khamashta MA, Wahl D, Regnault V, Lecompte T. Letters:antiphospholipid antibodies and risk for recurrent vascular events. JAMA 2004;291:2701-2.
28. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, De Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009;8:998-1005.
29. Ames PR, Ciampa A, Margaglione M, Scenna G, Iannaccone L, Brancaccio V. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation. Thromb Haemost 2005;93:694-9.
30. Finazzi G,Marchioli R, Brancaccio V, Schinco P,Wisloff F,Musial J, et al. A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-53.
31. Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2010;7:15-8.
32. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
33. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74.
34. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Ageno W, et al. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001;345:165-9.
35. Derksen RHWM, De Groot PG. Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus 2010;19:470-4.
36. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’angelo A, et al. Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy). G Ital Cardiol 1977;27:231-43.
37. Scoble T, Wijetilleka S, Khamashta MA. Management of refractory anti-phospholipid syndrome. Autoimmun Rev 2011;10:669-73.
38. Tincani A, Andreoli L, Casu C, Cattaneo R, Meroni P. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus 2010;19:432-5.
39. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome. JAMA 2006;295:1050-7.
40. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British committee for Standard in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47-58.
41. Pengo V, Ruiz-Irastorza G, Denas G, Andreoli L, Khamashta MA, Tincani A. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome. "PROS" and "CONS". Autoimmun Rev 2012;11:577-80.
42. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011;20:206-18.
43. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007;57:1487-95.